消息

ACI Worldwide has deepened its footprint in European payments by becoming a principal member of the European Payments Initiative (EPI) and integrating the EPI‑backed Wero instant‑payments wallet into its Payments Orchestration Platform. The partnership extends Wero’s availability from its launch in 2024 in Belgium, France and Germany to the Netherl...

全文

Medincell's financial performance demonstrates a disciplined approach to investments and a focus on generating recurring royalty revenues. As the company transitions towards multiple commercialized products, it is expected to generate sustainable value for patients, partners, and shareholders.

全文

The company's liquidity position was strengthened by a successful fundraising of €48.2 million in March 2026, attracting top-tier US and European healthcare investors. This influx of capital positions Medincell for future growth initiatives. The "Shift to Growth" strategy is advancing, with the expected commercial launch of Olanzapine LAI by Teva i...

全文

Medincell's FY 2025-26 financials reflect a year of solid execution and transition towards multiple commercialized innovative products based on its technology. The company generated €24.3 million in total revenues, with UZEDY royalties contributing €9.3 million, confirming the evolution of the revenue model. Operating expenses increased by 17% year...

全文

Recent earnings outlook improvements are reflected in a consensus estimate rise from $4.04 to $4.73, following an upward revision. TX’s quarterly price gain of 32.2% and a year‑over‑year increase of 65.61% outpace the Steel‑Producers peers and the S&P 500, which gained 11.66% and 24.19% respectively. The stock’s average 20‑day trading volume of 548...

全文

Ternium S.A. (TX) has shown strong short‑term momentum, with a 15.8% four‑week price change and a 32.2% gain over the past 12 weeks. The stock’s beta of 1.28 indicates it moves 28 % higher or lower than the market. TX’s Momentum Style Score is B and the Zacks Rank is #2 (Buy), both suggesting continued price growth. The company trades at a price‑to...

全文

The aggregated data position epcoritamab as a potential first‑line or bridging therapy for high‑risk follicular lymphoma and an alternative for elderly DLBCL patients who are not candidates for anthracycline‑based chemotherapy. Regulatory filings, pricing decisions and fixed‑duration treatment strategies for relapsed or refractory follicular lympho...

全文

In the elderly diffuse large B‑cell lymphoma (DLBCL) population, two separate studies highlighted epcoritamab’s activity. The Phase 2 EPCORE DLBCL‑3 trial reported a 67 % overall response rate and a 58 % complete response rate, with a safety profile in line with expectations. The Phase 1b/2 EPCORE NHL‑2 trial achieved a 93 % overall response rate a...

全文

Genmab’s most recent clinical data reinforce the therapeutic promise of epcoritamab. A post‑hoc subgroup analysis of the Phase 3 EPCORE FL‑1 trial showed that epcoritamab combined with rituximab and lenalidomide (R2) delivers a consistently reduced risk of disease progression or death, with hazard ratios below 0.3 across all FLIPI scores (0–2 and 3...

全文

Orbis Investment Management Limited announced on 12 June 2026 that it now controls 3,112,476 voting shares in Genmab A/S, representing 4.99 % of the company’s share capital. The notification, filed under Section 30 of the Danish Capital Markets Act, is likely to influence investor sentiment and market perception but does not alter Genmab’s operatio...

全文